Johnson & Johnson sold 25.4 million shares of Elan Corp. ending a relationship started four years ago to develop the Alzheimer's disease drug bapineuzumab.
Continue Reading »»
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.
© 2018 BridgeTower Media. All information on this site is copyrighted by BridgeTower Media.
All images are the sole property of BridgeTower Media and no rights are granted for any use without the express written consent of BridgeTower Media.